19. Breast cancer patient-derived scaffolds enhance the understanding of PD-L1 regulation and T cell cytotoxicity
In a recent publication in the well-respected journal Communications Biology, Iscaff Pharma’s innovative patient-derived scaffold technology explored 110 primary breast cancers to reveal the profound impact of cancer microenvironments on immune regulators, paving the way for personalized cancer treatment strategies. By correlating PD-L1 expression variations with clinical observations and specific proteins, Iscaff Pharma’s approach enhances the precision of immune-based cancer therapies by offering treatment-predictive information. The article highlights the need to further address cancer stem cell features in surviving cancer cells after treatment, providing clinically relevant insights to guide the development of more effective immune-based therapies.
